Trevi files for $86M IPO re chronic itching drug
New Haven biopharma Trevi Therapeutics is planning to go public in hopes of raising $86 million to pay for late-stage clinical trials of its drug...
Home >
Access the latest news, business developments, company updates, industry trends, events and more.
New Haven biopharma Trevi Therapeutics is planning to go public in hopes of raising $86 million to pay for late-stage clinical trials of its drug...
In filings to the U.S. Securities & Exchange Commission between January and March of this year, Connecticut companies reported raising $109 million in the aggregate,...
The University of New Haven has announced that its first-ever comprehensive fundraising campaign has surpassed its original goal of $100 million. The ambitious nine-figure target,...
SpringWorks Therapeutics reports the closing of a $125 million Series B preferred stock financing led by Perceptive Advisors. Proceeds from the financing will be used to...
Arvinas reports that two members of the senior leadership team were appointed to expanded roles at the company. Andy Crew, Ph.D., has been appointed Chief Technology...
ADAM, a biotechnical initiative based at BioCT Innovation Commons in Groton, has set a new milestone in in medical technology by launching the 3D bioprinting...
Greenfield BioVentures is an investment company focused on early-stage science in the biopharmaceuticals space. Its preferred investments are typically in pre-clinical stages of experimentation and in...
In the latest sign that the major biopharma players are eagerly joining the big tech rush on the gene therapy market, Pfizer has snagged an...
GestVision reports researchers have demonstrated that CRD (Congo Red Dot) urine diagnostic test results strongly correlate with a diagnosis of preeclampsia. “This is an important...
Biohaven Pharmaceutical Holding Company has purchased an FDA Priority Review Voucher to use with the NDA submission of rimegepant Zydis® ODT in the second quarter of 2019 …...